EGFRvIII mutation	Squamous Cell Carcinoma of Head and Neck	EGFRvIII mutation	Squamous Cell Carcinoma of Head and Neck	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
EGFRvIII mutation	Glioblastoma	EGFRvIII mutation	Glioblastoma	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3
EGFRvIII mutation	Astrocytoma	EGFRvIII mutation	Astrocytoma	WSD0922 Sensitive: C3 – Early Trials WSD0922 Sensitive : C3	WSD0922 Sensitive: C3 – Early Trials WSD0922 Sensitive : C3
EGFRvIII mutation	Glioblastoma	EGFRvIII mutation	Glioblastoma	AMG 595 Sensitive: C3 – Early Trials AMG 595 Sensitive : C3	AMG 595 Sensitive: C3 – Early Trials AMG 595 Sensitive : C3
EGFRvIII mutation	Glioblastoma	EGFRvIII mutation	Glioblastoma	EGFRvIII-targeted CAR-T immunotherapy Sensitive: D – Preclinical EGFRvIII-targeted CAR-T immunotherapy Sensitive : D	EGFRvIII-targeted CAR-T immunotherapy Sensitive: D – Preclinical EGFRvIII-targeted CAR-T immunotherapy Sensitive : D
EGFRvIII mutation	Glioma	EGFRvIII mutation	Glioma	Bay846 Sensitive: D – Preclinical Bay846 Sensitive : D	Bay846 Sensitive: D – Preclinical Bay846 Sensitive : D
EGFRvIII mutation	Non Small Cell Lung Cancer	EGFRvIII mutation	Non Small Cell Lung Cancer	gefitinib Sensitive: D – Preclinical gefitinib Sensitive : D	gefitinib Sensitive: D – Preclinical gefitinib Sensitive : D
EGFRvIII mutation	Solid Tumor	EGFRvIII mutation	Solid Tumor	TAS2940 Sensitive: D – Preclinical TAS2940 Sensitive : D	TAS2940 Sensitive: D – Preclinical TAS2940 Sensitive : D

EGFRvIII mutation

Associations